Evidence map›Paper›PMID 39749681›Full record

ArticleDrug development research2025

An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB.

Alessandro Giustini, Alice Maiocchi, Ilaria Serangeli, Martina Pedrini, Anna Quintiliani, Valentina Sabato, Francesca Bonato, Pierfausto Seneci, Giuseppe Lupo, Daniele Passarella and 1 more

Abstract read
In one paragraph

Article in Drug development research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandro GiustiniDepartment of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.
Alice MaiocchiDepartment of Chemistry, University of Milan, Milan, Italy.
Ilaria SerangeliDepartment of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.
Martina PedriniDepartment of Chemistry, University of Milan, Milan, Italy.
Anna QuintilianiDepartment of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.
Valentina SabatoDepartment of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.
Francesca BonatoDepartment of Chemistry, University of Milan, Milan, Italy.
Pierfausto SeneciDepartment of Chemistry, University of Milan, Milan, Italy.
Giuseppe LupoDepartment of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.
Daniele PassarellaDepartment of Chemistry, University of Milan, Milan, Italy.
Elena MirandaDepartment of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-0586-8795

Funding

Fondazione Telethon - Italy, Grantn.GMR23T1217This work was supported by Sapienza University of Rome, Italy (Sapienza Research Grants 2021)
6 · The paper itself

Abstract

Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is a neurodegenerative pathology caused by accumulation of mutant neuroserpin (NS) polymers inside the endoplasmic reticulum (ER) of neurons, leading to cellular toxicity and neuronal death. To date, there is no cure for FENIB, and only palliative care is available for FENIB patients, underlining the urgency to develop therapeutic strategies. The purpose of this work was to create a cellular system designed for testing small molecules able to reduce the formation of NS polymers. Our results show the generation and characterisation of a novel cell culture model for FENIB based on neural stem progenitor cells (NPCs) with inducible expression of either wild type (WT) or G392E NS, a variant that causes severe FENIB. We also report the use of these novel cell lines to explore the effects of four different proteolysis targeting chimaera (PROTAC) compounds, small bivalent molecules engineered to bind to the E3 ubiquitin ligase cereblon, and to NS through a recruiting motif based on the small molecule embelin. This approach aims to enhance the degradation of mutant NS after retro-translocation to the cytosol by facilitating its targeting to the proteasome. Our results show little toxicity and no variation in NS levels with any of the compounds tested. In conclusion, this work sets the basis for future attempts to identify molecules able to prevent NS accumulation inside the ER of cultured cells.

Indexed as

Neural Stem CellsNeuroserpinSerpinsAnimalsHumansInclusion BodiesNeurodegenerative DiseasesNeuropeptidesNeuropeptidesNeuroserpinSerpinscereblonembelinFENIBneural progenitor cellsneuroserpinPROTAC

Identifiers

PMID39749681
PMCPMC11696822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.